Drug Trial Radar · NCT01014988
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
Last checked: Nov 20, 2026Latest source record: Mar 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
202
Actual
Start
Nov 2009
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection. A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir.
Conditions
- Influenza, Human
Interventions
zanamivir aqueous solutionDrug
Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Adverse Event (AE) Considered to be Related to Study TreatmentTime frame: Up to post-treatment (PT) + 23 days
- Number of Participants With Any Severe or Grade 3/4 AEsTime frame: Up to post-treatment (PT) + 23 days
- Number of Participants With Any Severe or Grade 3/4 Treatment-related AETime frame: Up to post-treatment (PT) + 23 days
- Number of Participants Who Permanently Discontinued the Study Treatment Due to an AETime frame: Up to 10 days
- Number of Participants Who Were Permanently Discontinued From the Study Due to an AETime frame: Up to post-treatment (PT) + 23 days
- Number of Participants With the Indicated Clinical Chemistry Values Relative to the Normal Range at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
- Number of Participants With the Indicated Hematology Values Relative to the Normal Range at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
- Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Clinical Chemistry ToxicitiesTime frame: Up to post-treatment (PT) + 23 days
- Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Hematology ToxicitiesTime frame: Up to post-treatment (PT) + 23 days
- Median Heart Rate at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
- Median Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
- Median Oxygen Saturation Measured Via Transcutaneous Oximetry (TCPO2) at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
- Median Respiration Rate at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
- Median Body Temperature at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
- Number of Participants Assessed as Normal/Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at Baseline (Day 1)Time frame: Baseline (Day 1)
- Median Corrected QT Interval (QTc) for Heart Rate by Fridericia's Formula (QTcF) and Bazett's Formula (QTcB) at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
Locations
110 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
San Diego, California
GSK Investigational Site
Stamford, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Decatur, Georgia
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Topeka, Kansas
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Saint Paul, Minnesota
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Butte, Montana
GSK Investigational Site
Camden, New Jersey
GSK Investigational Site
New Hyde Park, New York
GSK Investigational Site
Chapel Hill, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Toledo, Ohio
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Memphis, Tennessee
GSK Investigational Site
Memphis, Tennessee
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Salt Lake City, Utah
GSK Investigational Site
Richmond, Virginia
GSK Investigational Site
Milwaukee, Wisconsin
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.